- Previous Close
1.200 - Open
1.200 - Bid 1.200 x --
- Ask 1.220 x --
- Day's Range
1.200 - 1.200 - 52 Week Range
1.030 - 1.400 - Volume
832,000 - Avg. Volume
301,081 - Market Cap (intraday)
1.801B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
3.00 - EPS (TTM)
0.400 - Earnings Date --
- Forward Dividend & Yield 0.08 (6.67%)
- Ex-Dividend Date Sep 16, 2024
- 1y Target Est
--
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. Dawnrays Pharmaceutical (Holdings) Limited was founded in 1995 and is headquartered in Wan Chai, Hong Kong.
www.dawnrays.com1,175
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2348.HK
View MorePerformance Overview: 2348.HK
Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2348.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2348.HK
View MoreValuation Measures
Market Cap
1.80B
Enterprise Value
687.93M
Trailing P/E
3.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.57
Price/Book (mrq)
0.52
Enterprise Value/Revenue
0.60
Enterprise Value/EBITDA
0.88
Financial Highlights
Profitability and Income Statement
Profit Margin
52.20%
Return on Assets (ttm)
3.77%
Return on Equity (ttm)
18.41%
Revenue (ttm)
1.08B
Net Income Avi to Common (ttm)
563.11M
Diluted EPS (ttm)
0.400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.69B
Total Debt/Equity (mrq)
5.75%
Levered Free Cash Flow (ttm)
-9.03M